Our publication in the journal Nature Communications brings the Choroid-Chip to light. This immunocompetent model incorporates melanocytes, microvascular endothelial cells, retinal-pigmented epithelial cells and perfusion of peripheral immune cells to study the ocular toxicity of molecular targeted therapies in oncology.
